Sophonix Co., Ltd. was founded in 2017, the headquarter is located in Beijing. Sophonix has dual R&D centers in California and Beijing. The KOLs possess over 15 years of expertise and experience in the field of IVD and are dedicated to provide more convenient, accurate and reliable diagnosis services and products through technological innovations. Sophonix has a complete product portfolio of independent intellectual property rights, including Automatic Chemiluminescence Immunoassay Analyzing System (CLIA method), pathological diagnosis system (Automatic Immunohistochemical Staining Machine) and molecular diagnosis system (Isothermal Nucleic Acid Amplification Analyzer, LAMP technology) and a broad panel of the compatible tests, which are suitable for POCT rapid detection sites.
1. We successfully developed the single-cartridge automated chemiluminescence Immunoassay (CLIA) POCT analyzing system, MS-Fast series products, which has obtained the ISO13485, CE marking certificate, FDA as well as China NMPA registration certificate.
2. The pathological diagnostics product line consists of the Ultra 30 and Ultra 60 which suit for medium to large laboratories to meet various needs and requirements of different customers.
3. In the molecular diagnostics field, we have developed the GM-Fast-60 system, which takes LAMP technology and could be used for rapid detection of respiratory diseases, such as the SARS-CoV-2, H1N1 influenza, etc.